Walleye Capital
TLSI icon

Walleye Capital’s TriSalus Life Sciences TLSI Stock Holding History

Walleye Capital’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,376
Closed -$66.3K – 5560
2024
Q3 		$66.3K Buy
+14,376
New +$76.1K ﹤0.01% 4550
2022
Q4 		– Sell
-12,898
Closed -$128K – 3635
2022
Q3 		$128K Hold
12,898
– – ﹤0.01% 2321
2022
Q2 		$127K Hold
12,898
– – ﹤0.01% 1682
2022
Q1 		$126K Buy
12,898
+1,603
+14% +$15.8K ﹤0.01% 1681
2021
Q4 		$112K Sell
11,295
-1,119
-9% -$11.1K ﹤0.01% 1644
2021
Q3 		$123 Buy
+12,414
New +$122K ﹤0.01% 1287

Other funds holding TLSI

WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GL
Graypoint LLC Albany, New York $1.78B AUM 16.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Walleye Capital's TLSI Position: Q4 2024 in Review

Walleye Capital sold out of TriSalus Life Sciences (TLSI) in Q4 2024, closing a stake of 14,376 shares — an estimated $66.3K sold.

Walleye Capital first reported a position in TLSI in Q3 2021 and held it in 6 quarters. The position peaked at $128K in Q3 2022. 30 funds tracked by Wall St. Rank hold TLSI as of Q4 2024.

  • Walleye Capital reported no remaining TriSalus Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Walleye Capital sold 14,376 TriSalus Life Sciences shares in Q4 2024, an estimated $66.3K.
  • Walleye Capital first reported a position in TriSalus Life Sciences in Q3 2021 and held it in 6 quarters.
  • Walleye Capital's TriSalus Life Sciences position peaked at $128K in Q3 2022.
  • 30 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2024.

Based on Walleye Capital's 13F filing for Q4 2024, filed 13 Feb 2025.